The FDA has delayed a decision on whether to approve emergency use of Moderna's COVID-19 vaccine in 12- to 17-year-olds until at least January.
"On Friday evening, the FDA informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination. The FDA notified Moderna that this review may not be completed before January 2022," the company said."The safety of vaccine recipients is of paramount importance to Moderna. The company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence.
Several countries have raised concerns that the Moderna vaccine increases the risk of myocarditis in men aged 18-30, and officials in Finland and Sweden have recommended against the use of Moderna for men younger than 30, theBut Moderna said Sunday that the"U.S. Centers for Disease Control and Prevention [CDC] and the World Health Organization [WHO] have stated that myocarditis following vaccination with mRNA vaccines has been rare and generally mild.
"It is estimated that over 1.5 million adolescents have received the Moderna COVID-19 vaccine. To date, the observed rate of myocarditis reports in those less than 18 years of age in Moderna's global safety database does not suggest an increased risk of myocarditis in this population," the company statement added."The company does not yet have access to data from some recent international analyses.
The Moderna vaccine is authorized in the United States for people 18 and older, and the company asked the FDA in June to authorize it for adolescents.On Sunday, the company also said it will delay seeking FDA authorization of its vaccine for children ages 6-11.In May, the FDA authorized the emergency use of the Pfizer vaccine for adolescents aged 12 to 15. And on Friday, the agency cleared the vaccine for children aged 5 to 11, administered in two doses of 10 micrograms each.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says FDA needs more time to review its Covid vaccine for teensModerna said the FDA needs more time to complete its review of its Covid-19 vaccine for 12-to-17-year-olds before granting emergency use authorization.
Read more »
Moderna says FDA needs more time to complete review of its COVID-19 shot for adolescentsModerna Inc said on Sunday it has been told that the U.S. Food and Drug Administration will require additional time to complete its assessment of the company's COVID-19 vaccine for use in adolescents aged 12 to 17 years.
Read more »
FDA delaying decision on Moderna Covid vaccine for adolescentsRegulators delaying decision on vaccine for 12-17 year olds while studying rare risk of heart inflammation.
Read more »
FDA Authorizes Pfizer COVID Vaccine for KidsCoronavirus vaccines should be available for 28 million children in the United States as early as next week
Read more »
FDA Authorizes Use Of Pfizer's COVID-19 Vaccine For Kids 5-11The Food and Drug Administration (FDA) has just authorized Pfizer's COVID-19 vaccine for children ages 5-11.
Read more »
The FDA told Moderna it needs more time to review use of their COVID-19 vaccine for kids'The Company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence,' Moderna said.
Read more »